Oncology · Small MoleculeRegulatory Approvalcommercialmid-term

FDA Grants AP Status for Lenalidomide ANDA210480 by Alvogen

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/31/2026, 12:32:28 AM

Assessment confidence: 55% · The main uncertainty is limited high-relevance corpus coverage for this sub-indication.

Executive Thesis

The FDA's grant of Abbreviated Approval status for Alvogen's generic lenalidomide introduces significant competition in the oncology market. This could impact pricing and market share for existing branded therapies, necessitating strategic adjustments by pharma companies with similar products. Regulatory context from FDA (FDA AP — PREGABALIN (SUPPL)) supports the near-term read. Assessment grounded in 22 ranked evidence items (4 high-relevance).

Strategic Assessment

Portfolio teams should assess the impact of generic lenalidomide on pricing and market share for existing branded therapies. The strongest clinical anchor is A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors (ClinicalTrials.gov), mechanism alignment (io ). In Oncology · Small Molecule, 5 regulatory and 4 competitive items passed relevance filtering for Alvogen.

Competitive Pressure

The most relevant competitive pressure comes from Karyopharm's XPOVIO (Selinexor) NDA212306 Receives Approval Status from FDA (Humanexa Signals) — mechanism alignment (io ). Secondary pressure from FDA Accepts Lenalidomide ANDA Submission from Torrent. This approval allows Alvogen to market a generic version of lenalidomide, increasing competition in the oncology market.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — PREGABALIN (SUPPL) (FDA). Entity match (alvogen); Regulatory pathway relevance (nda). The approval indicates compliance with FDA standards for generics but does not suggest immediate regulatory challenges for existing branded products.

Key Opportunities

The entry of a generic version of lenalidomide may lead to price erosion and affect the revenue of branded therapies, particularly those currently dominating the oncology space.
On July 22, 2026, the Food and Drug Administration approved zidesamtinib (Jideytro, Nuvalent, Inc.) for adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) who received at least one prior ROS1 tyrosine kinase inhibitor (TKI).
Portfolio teams should assess the impact of generic lenalidomide on pricing and market share for existing branded therapies.

What Would Change This Assessment

This becomes more urgent if Monitor Alvogen's launch timeline and market uptake of the generic lenalidomide.
Additional medium- or high-relevance evidence would materially upgrade this assessment.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — PREGABALIN (SUPPL)
FDAhigh relevance
Entity match (alvogen); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — REVLIMID (SUPPL)
FDAhigh relevance
Sponsor/company relevance (Bristol Myers Squibb); Regulatory pathway relevance (nda)
FDA document
View source
FDA approves zidesamtinib for ROS1-positive non-small cell lung cancer
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
FDA AP — PADCEV (SUPPL)
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
FDA Approves New Treatment That Uses Donor Immune Cells to Prevent Serious Complications in Blood Cancer Patients
FDAmedium relevance
Moderate corpus alignment
FDA document
View source

A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors
ClinicalTrials.govhigh relevance
Mechanism alignment (IO )
FDA document
View source
Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM),
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
The Effect of Channa Striata and Curcuma Supplementation on Nutritional Status, Interleukin-6 Levels, and Quality of Life in Patients With Breast Cancer.
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Lenalidomide for Adult Histiocyte Disorders
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Relationship Between Clinical Status and Nerve Conduction Test Findings in Patients With Unilateral Hemiplegia
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

Karyopharm's XPOVIO (Selinexor) NDA212306 Receives Approval Status from FDA
Humanexa Signalshigh relevance
Mechanism alignment (IO )
FDA Accepts Lenalidomide ANDA Submission from Torrent
Humanexa Signalsmedium relevance
Moderate corpus alignment
FDA Grants Approval for Pomalidomide Supplement by Mylan
Humanexa Signalsmedium relevance
Moderate corpus alignment
FDA Approves JIDEYTRO (ZIDESAMTINIB) for Nuvalent Inc.
Humanexa Signalsmedium relevance
Moderate corpus alignment

Inflammation and carcinogenesis: molecular targets and small-molecule intervention strategies.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Trial watch: antibody-drug conjugates in cancer therapy.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Intratumoral enrichment and suppressive activity of DP8α regulatory T cells in human colorectal cancer.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
In vitro screening of compounds for targeting gastric cancer with Y220C p53 mutation: a molecule combining zinc chelation and Michael acceptor drives CDKN1 and BBC3 expression to restore a p53-depende
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Early prediction of minimal residual disease in colorectal cancer via SEPTIN9 methylation status in circulating tumor DNA.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Comparison of epcoritamab, lenalidomide, and rituximab versus usual care in relapsed/refractory follicular lymphoma.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Inhibition of STAT3-mediated glycolysis by bruceine D suppresses non-small-cell lung cancer progression in vitro and in vivo.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Type 2 diabetes remission in gynaecologic oncology patients completing an acute preoperative weight loss protocol: a case series.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Alvogen

Commercial impact

medium

The entry of a generic version of lenalidomide may lead to price erosion and affect the revenue of branded therapies, particularly those currently dominating the oncology space.

Regulatory impact

low

The approval indicates compliance with FDA standards for generics but does not suggest immediate regulatory challenges for existing branded products.

What to watch

Monitor Alvogen's launch timeline and market uptake of the generic lenalidomide.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.